BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF)(TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that significant enhancement of critical performance factors for many monoclonal antibodies (MAbs) appears possible through a novel cross linking technology developed by the company. Laboratory studies of the company’s first product candidate, DXL625 (CD20), for the prospective treatment of non-Hodgkin’s lymphoma, indicated that DXL625, an anti-CD20 monoclonal antibody enhanced with InNexus’ DXL™ technology, may afford greater potency, binding affinity, and related characteristics, than the parent compound.
